Page last updated: 2024-11-04

vorinostat and Pruritus

vorinostat has been researched along with Pruritus in 3 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.

Research Excerpts

ExcerptRelevanceReference
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)."9.12Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007)
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)."7.74Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007)
"The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL)."5.12Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). ( Chiao, JH; Duvic, M; Frankel, SR; Hazarika, P; Kelly, C; Ni, X; Reilly, JF; Richon, VM; Ricker, JL; Talpur, R; Zhang, C, 2007)
"To discuss vorinostat approval for treatment of cutaneous manifestations of advanced cutaneous T-cell lymphoma (CTCL)."3.74Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. ( Abraham, S; Booth, BP; Dagher, R; Farrell, A; Harapanhalli, RS; He, K; Jee, JM; Johnson, JR; Justice, R; Mann, BS; Morse, DE; Pazdur, R; Pope, S; Sridhara, R; Verbois, L, 2007)
"Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL)."1.42Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. ( Benoit, BM; Cedeno-Laurent, F; Kim, EJ; Rook, AH; Singer, EM; Vittorio, CC; Wysocka, M; Yosipovitch, G, 2015)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cedeno-Laurent, F1
Singer, EM1
Wysocka, M1
Benoit, BM1
Vittorio, CC1
Kim, EJ1
Yosipovitch, G1
Rook, AH1
Duvic, M1
Talpur, R1
Ni, X1
Zhang, C1
Hazarika, P1
Kelly, C1
Chiao, JH1
Reilly, JF1
Ricker, JL1
Richon, VM1
Frankel, SR1
Mann, BS1
Johnson, JR1
He, K1
Sridhara, R1
Abraham, S1
Booth, BP1
Verbois, L1
Morse, DE1
Jee, JM1
Pope, S1
Harapanhalli, RS1
Dagher, R1
Farrell, A1
Justice, R1
Pazdur, R1

Trials

1 trial available for vorinostat and Pruritus

ArticleYear
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
    Blood, 2007, Jan-01, Volume: 109, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dehydration; Disease Progression; Disease-Fre

2007

Other Studies

2 other studies available for vorinostat and Pruritus

ArticleYear
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
    Clinical immunology (Orlando, Fla.), 2015, Volume: 158, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Depsipeptides; Dexamethasone; Female; Histone Deacetylase Inhibitors

2015
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Apr-15, Volume: 13, Issue:8

    Topics: Animals; Anticarcinogenic Agents; Cats; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II

2007